OXIS International, Inc. (OTCMKTS:OXIS) has announced details about the development of its Immunotherapeutic treatment, developed by its subsidiary Oxis Biotech. The CEO of Oxis Biotech, Anthony J. Cataldo, announced that his company has been trying to target triple-negative breast cancer, through this treatment. Additional targets for the drug would include multiple myeloma and osteolytic lesions. The company believes that with the launch of this therapy they would be addressing unmet medical needs. The developments with respect to immunotherapies are done in partnership with Multi-Cell Immunotherapeutic (MCIT).
MCIT’s proprietary anti-body drug conjugate (ADC) is the key ingredient for the therapy. The ADC is formed with various cleavable linkers that can carry tethered drugs and deliver them at an intracellular and extracellular level. Additionally, the anti-bodies are capable of carrying multiple drugs at the same time. The best part is that the drugs are released at their designated locations, without any modifications to their original form. However, the company is not entirely relying on MCIT for further development. The company has been working on bi-specific immune cell engagers. These drugs would direct the patient’s immune system to attack cancerous cells.
The unique thing about Oxis International is that most of its drugs are derived from cannabinoid. Additionally, the company mostly focuses on the shortcomings of existing medical treatments, thus always trying to come up with something different. To accomplish this goal, the company has developed affiliations with a number of research institutes and other companies in the cannabis industry. The CEO of the company, Tony Cataldo, had issued a letter to shareholders in February, stating that Biotech had a great FY2014. He also wrote that Biotech has experienced a change in direction this year. The company has strategically chosen a few areas for cancer drug development and is now working on it.
OXIS International, Inc. (OTCMKTS:OXIS) closed at $0.037, dropping by 5.13%. The company trades nearly 6 million shares in the market, with a 52 week range of $0.00-$0.07.